Review| Volume 56, ISSUE 2, P77-83, August 1997

A study on the effects of Norplant® implantable contraceptive on lipid, lipoprotein, and apolipoprotein metabolism in Singaporean women

  • Kuldip Singh
    Name and address for correspondence: Kuldip Singh, Associate Professor & Senior Consultant, Department of Obstetrics and Gynaecology, The National University of Singapore, The National University Hospital, Lower Kent Ridge Road, Singapore 119074. Tel: +65 772 4261; Fax: +65 779 4753
    Department of Obstetrics and Gynaecology, National University Hospital, Singapore
    Search for articles by this author
  • S.S. Ratnam
    Department of Obstetrics and Gynaecology, National University Hospital, Singapore
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      The Norplant® subdermal implants system is rapidly becoming acceptable as a contraceptive system all over the world. Earlier studies in Singapore indicated that the implants do not appear directly contributory to cardiovascular risk. However, extraneous environmental effects could have contributed to the observed changes.
      In this study, when nonsteroid copper intrauterine device (IUD) users were used as control, we have shown that the findings are in concordance with the results of the earlier studies. There was a decrease in serum triglycerides, total cholesterol, and HDL and LDL cholesterol over the period of study. However, despite these changes, the HDL cholesterol/total cholesterol ratio remained stable and was above 0.200. As regards apolipoprotein, there was generally a significant fall in apolipoprotein AI, AII, and B. As a result, the apolipoprotein Math Eq ratio showed a significant decrease in the first 3 months before increasing close to its preinsertion value at 2 years. Similarly, the apolipoprotein Math Eq ratio also stabilized at the end of 2 years.
      This study thus confirms our earlier findings that Norplant implants do not appear directly contributory to cardiovascular risk.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Singh K
        • Viegas OAC
        • Ratnam SS
        A three-year evaluation of metabolic changes in Singaporean Norplant acceptors.
        Adv Contracept. 1990; 6: 11-21
        • Singh K
        • Viegas OAC
        • Loke DFM
        • Ratnam SS
        Effect of Norplant implants on liver, lipid and carbohydrate metabolism.
        Contraception. 1992; 45: 141-153
        • Gorton T
        • Castelli WP
        • Hjortland MC
        • Kannel WB
        • Dawber TR
        High density lipoprotein as a protective factor against coronary heart disease.
        A J Med. 1977; 62: 707-711
        • Kannel WB
        • Castelli WP
        • Gordon T
        Cholesterol in the prediction of atherosclerotic disease.
        Ann Intern Med. 1979; 90: 85-91
        • Haarbo J
        Impact of hormone replacement on serum lipids, lipoproteins, body composition and atherosclerosis: clinical and experimental studies.
        Dan Med Bull. 1994; 41: 412-422
        • Haarbo J
        Hormone replacement therapy and cardiovascular disease: the rabbit model.
        Br J Obstet Gynaecol. 1996; 103: 49-52
        • Clarkson TB
        Hormone replacement therapy and coronary artery atherosclerosis: the monkey model.
        Br J Obstet Gynaecol. 1996; 103: 53-58
        • Hirvonen G
        • Malkonen M
        • Manninen V
        Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
        N Engl J Med. 1981; 304: 560-563
        • Fahraeus L
        • Larsson-Cohn U
        • Wollentin L
        L-norgestrel and progesterone have different influences on plasma lipoproteins.
        Eur J Clin Invest. 1983; 13: 447-453
        • Croxatto HR
        • Diaz S
        • Robertson DN
        • Pavez M
        Clinical chemistry in women treated with levonorgestrel implants (Norplant®), or TCu-200-IUD.
        Contraception. 1983; 27: 281-288
        • Shaaban MM
        • Abdalla SI
        • Anch SA
        • Daruich HA
        Effect of levonorgestrel contraceptive implants Norplant® on serum lipids.
        Contraception. 1984; 30: 413-419
        • Holma P
        • Robertson DN
        Cholesterol and HDL cholesterol values in women during use of subdermal implant releasing levonorgestrel.
        Contraception. 1985; 32: 163-171
        • Castelli WP
        • Doyle JI
        • Gordon T
        • et al.
        HDL-cholesterol and other lipids in coronary heart disease.
        Circulation. 1977; 55: 767-772
        • Rabe T
        • Thuro Hc
        • Goebel K
        • Borchardt C
        • Grunuwald K
        • Runnebaun B
        Lipid metabolism in Norplant-2® users—a two-year follow-up study. Total cholesterol, triglycerides, lipoproteins and apolipoprotein.
        Contraception. 1992; 45: 21-37